Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Vertex Pharma

This page shows the latest Vertex Pharma news and features for those working in and with pharma, biotech and healthcare.

Health secretary’s ‘rip off’ remarks anger UK pharma

Health secretary’s ‘rip off’ remarks anger UK pharma

Health secretary’ s ‘ rip off’ remarks anger UK pharma. Row with Vertex has tainted government-industry relations. ... Leslie Galloway, chairman of EMIG, the UK industry group for small-to-medium pharma companies says these factors are endangering

Latest news

  • Allergan builds on gene editing deal Allergan builds on gene editing deal

    genes. The approach has been making the rounds quite recently in the pharma space, but this ground-breaking gene therapy is struggling to win over the FDA. ... Back in March, the US regulator halted Vertex Pharma’s planned trial involving CRISPR for

  • NHS England to Vertex: come clean on Orkambi offer NHS England to Vertex: come clean on Orkambi offer

    NHS England wants Vertex Pharma to waive its non-disclosure agreement on the price it intends to charge for cystic fibrosis drug Orkambi so the public can “form their own ... Vertex’s list price for Orkambi is around £100, 000 a year per patient,

  • Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’ Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’

    Vertex to Theresa May: Orkambi verdict ‘ threatens bio investment’. CEO writes open letter to prime minister. ... Fresh from the news that the NHS in England still isn’t minded to fund treatment with its cystic fibrosis therapy Orkambi, Vertex

  • Reshma Kewalramani joins Vertex Pharmaceuticals as CMO Reshma Kewalramani joins Vertex Pharmaceuticals as CMO

    Vertex Pharmaceuticals, a biotech known for its clinical development programmes in cystic fibrosis, has appointed a new chief medical officer in the form of Reshma Kewalramani. ... Jeffrey Leiden, chairman, president and chief executive officer of Vertex,

  • Vertex's two-drug cystic fibrosis treatment cleared in US Vertex's two-drug cystic fibrosis treatment cleared in US

    Vertex's two-drug cystic fibrosis treatment cleared in US. FDA approves Symdeko, which combines Kalydeco and tezacaftor. ... Vertex Pharma has won an FDA green light for a third product for cystic fibrosis, and its second combination therapy for the

More from news
Approximately 5 fully matching, plus 19 partially matching documents found.

Latest Intelligence

  • The challenges of making genomics a reality for patients today, not tomorrow The challenges of making genomics a reality for patients today, not tomorrow

    The report singles out Vertex among a handful of successful biotech companies with highly innovative products. ... Dr Gillian Burgess is site head of UK Research and Vice President at Vertex.

  • Deal Watch table for November 2014 Deal Watch table for November 2014

    For an indepth analysis of these deals, read'Pharma deals during November 2014'. ... Omega Pharma / Perrigo. OTC portfolio. Company acquisition. 4, 500. Cystic Fibrosis Foundation /Royalty Pharma.

  • Pharma deals during November 2014 Pharma deals during November 2014

    Reckitt Benckiser(RB) is spinning out its pharma business unit, under the name Indivior. ... On a mission. Continuing its trend of helping companies monetise their future income streams, Royalty Pharma is buying royalties in Vertex Pharmaceutical's

More from intelligence
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • BMS appoints three independent directors BMS appoints three independent directors

    Meanwhile, Matthew Emmens and Theodore Samuels also join the pharma firm's board of directors. ... Since beginning his pharmaceutical career 40 years ago, Emmens has served as president, chief executive officer and chairman of Vertex Pharma, chief

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Unilever. Vasopharm. Vertex. Vetoquinol. Vifor Pharma. VR1 Inc. Wyss Center. Xenetic Biosciences.

  • Random42 Scientific Communication

    Collegium Pharmaceutical. CSL Behring. Dainippon Sumitomo Pharma. Daiichi-Sankyo. DePuy Synthes. DBV Technologies . ... Unilever. Vasopharm. Vertex. Vetoquinol. Vifor Pharma. VR1 Inc. Wyss Center. Xenetic Biosciences.

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Consulting at McCann Health

We are the strategic consultancy of McCann Health. We combine fresh and creative thinking with scientific and strategic depth...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Quick links

Infographics

Multimedia